Thoroughbred Financial Services LLC Acquires 2,200 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Thoroughbred Financial Services LLC lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 17,592 shares of the company’s stock after acquiring an additional 2,200 shares during the period. Thoroughbred Financial Services LLC’s holdings in Teva Pharmaceutical Industries were worth $285,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. New Covenant Trust Company N.A. bought a new position in Teva Pharmaceutical Industries during the first quarter worth about $28,000. EntryPoint Capital LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $30,000. Beach Investment Counsel Inc. PA acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at $48,000. Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $52,000. Finally, Industrial Alliance Investment Management Inc. acquired a new position in Teva Pharmaceutical Industries during the first quarter worth $54,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Eric A. Hughes sold 24,537 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.55% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. UBS Group increased their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Finally, Bank of America raised their target price on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $18.89.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $17.85 on Wednesday. The stock has a market cap of $20.22 billion, a price-to-earnings ratio of -43.54, a P/E/G ratio of 1.26 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a 12-month low of $8.06 and a 12-month high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The business’s 50-day simple moving average is $17.63 and its 200 day simple moving average is $16.02.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The business had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $3.99 billion. As a group, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.